Table 45, Use Of Generic Medications: Summary Of Results - NCBI

Trang chủ » G3 T40 » Table 45, Use Of Generic Medications: Summary Of Results - NCBI

Có thể bạn quan tâm

Table 45Use of generic medications: Summary of results

View in own window

StudyDesign/Risk of BiasStudy ArmsN analyzedOutcome and Time PeriodResults
Perlroth et al., 201362aCohort/MediumCongestive heart failureG1: enrolled in PDP receiving MTM with CMRG3: enrolled in MA-PD, receiving MTM with CMRChronic obstructive pulmonary diseaseG5: enrolled in PDP receiving MTM with CMRG7: enrolled in MA-PD, receiving MTM with CMRDiabetesG9: enrolled in PDP receiving MTM with CMRG11: enrolled in MA-PD, receiving MTM with CMRComparison—congestive heart failureG13: enrolled in PDP, usual careG14: enrolled in MA-PD, usual careComparison—Chronic obstructive pulmonary diseaseG15: enrolled in PDP, usual careG16: enrolled in MA-PD, usual careComparison—DiabetesG17: enrolled in PDP, usual careG18: enrolled in MA-PD, usual careG1: 12,658G3: 11,260G5: 16,372G7: 10,575G9: 16,545G11: 13,527G13: 156,441G14: 51,938G15: 184,350G16: 73,623G17: 133,925G18: 53,912Generic substitution ratio within 365 days after date of MTM enrollment (for interventions) or randomly-assigned date in 2010 (for comparators)Odds (95% CI)For CHF/COPD/diabetes drugsCongestive heart failureG1 vs. G13: 0.001 (-0.000, 0.002), p>0.05G3 vs. G14: 0.005 (0.003, 0.006), p<0.05Chronic obstructive pulmonary diseaseG5 vs. G15: -0.001 (-0.003, 0.000), p>0.05G7 vs. G16: 0.000 (-0.002, 0.002), p>0.05DiabetesG9 vs. G17: -0.000 (-0.000, 0.000), p>0.05G11 vs. G18: 0.000 (-0.000, 0.000), p>0.05
For non-CHF/COPD/diabetes drugsCongestive heart failureG1 vs., G13: 0.000 (-.002, 0.002), p>0.05G3 vs., G14: -0.010 (-0.013, -0.008), p<0.05Chronic obstructive pulmonary diseaseG5 vs., G15: 0.000 (-0.001, 0.003), p>0.05G7 vs., G16: 0.006 (0.003, 0.009), p<0.05DiabetesG9 vs., G17: -0.001 (-0.002, 0.000), p>0.05G11 vs., G18: -0.002 (-0.003, -0.001), p<0.05
Pindolia et al., 200942Cohort/HighG1: Telephone based MTM program (acceptors)G2: Usual medical care (refusers)G1: 292G2: 1081Increase in the overall use of generic drugsG1: 6%G2: 3%p not calculated because baseline percentages not provided
Winston et al., 200957Cohort/HighG1: Community pharmacy MTMG2: Pharmacist-staffed call center-based MTMG3: Educational mailingsG1: 21,336G2: 3,436G3: 49,021Weighted generic substitution ratio: 30-day equivalent claims divided by total number of claimsCalculated mean differences for G1 vs. G3: 1.2 (95% CI: 0.724 to1.676; p<0.001)Calculated mean difference for G2 vs. G3: 0.80 (95% CI: -0.246 to 1.846; p=0.134)
a

Perlroth et al. included MTM arms without CMR; these results were not eligible for our review because of our requirement for CMR. We have excluded groups 2, 4, 6, 8, 10, and 12 from our summary tables.

Abbreviations: CI = confidence interval; G = group; CMR = comprehensive medication review; MA-PD = Medicare Advantage Part D Plan; MTM = medication therapy management; N = number; PDP = Medicare Part D Plan.

Từ khóa » G3 T40